Literature DB >> 2217030

Lornoxicam, indomethacin and placebo: comparison of effects on faecal blood loss and upper gastrointestinal endoscopic appearances in healthy men.

S J Warrington1, N M Debbas, M Farthing, M Horton, A Johnston, A Thillainayagam, P Turner, H Ferber.   

Abstract

Forty-five healthy men aged 21-34 years took part in a double-blind, parallel-group, placebo-controlled study of the effects of 28 days' treatment with lornoxicam 4 mg twice daily or indomethacin 50 mg twice daily on faecal blood loss and the endoscopic appearances of gastric and duodenal mucosa. After an initial endoscopic examination, subjects received, intravenously, on day 0, autologous erythrocytes labelled with 51Cr. Complete daily faecal collections were then made from days 6-12, 20-26 and 34-40. The drug treatments or placebo were given from days 13-41. Faecal blood loss was calculated from 51Cr-specific activity of blood and faeces. Endoscopy was repeated 4-8 hours after the last dose of medication; mucosal appearance was graded on a 5-point scale. Lornoxicam caused no more adverse events than placebo; indomethacin caused more indigestion and central nervous system effects, and one subject in this group was withdrawn from the study. Median total blood losses during the pre-treatment and the second and fourth weeks of treatment were respectively 3.33, 3.95 and 5.71 ml for lornoxicam, 2.87, 7.04 and 7.75 ml for indomethacin, and 4.55, 3.64 and 4.13 ml for placebo. Differences between treatments were not statistically significant (P = 0.081 for second week of treatment, P = 0.383 for fourth week of treatment; Kruskal-Wallis test). The effect of chlortenoxicam on faecal blood loss in this study was thus intermediate between placebo and indomethacin, but within- and between-subject variability was such that the differences were not statistically significant. Endoscopic findings were normal in most subjects before and after all treatments, but indomethacin was associated with a slightly greater deterioration in endoscopic score and was the only treatment associated with Grade 3 appearance (in a single patient) in post-treatment endoscopy.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2217030      PMCID: PMC2429687          DOI: 10.1136/pgmj.66.778.622

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  12 in total

1.  A comparison of faecal blood loss caused by tenoxicam and piroxicam in normal healthy male volunteers.

Authors:  H A Bird; J Hill; W M Haw; J S Dixon; P A Harris; V Wright
Journal:  Curr Med Res Opin       Date:  1985       Impact factor: 2.580

2.  Fecal blood loss during isoxicam and piroxicam administration for 28 days.

Authors:  J W Hooper; J A Anslow; W S Martin; P Araujo; A Darke
Journal:  Clin Pharmacol Ther       Date:  1985-11       Impact factor: 6.875

3.  Effects of fenbufen, indomethacin, naproxen, and placebo on gastric mucosa of normal volunteers. A comparative endoscopic and photographic evaluation.

Authors:  F L Lanza; R S Nelson; B P Greenberg
Journal:  Am J Med       Date:  1983-10-31       Impact factor: 4.965

4.  Piroxicam, aspirin, and gastrointestinal blood loss.

Authors:  J R Bianchine; R R Procter; F B Thomas
Journal:  Clin Pharmacol Ther       Date:  1982-08       Impact factor: 6.875

5.  Gastrointestinal microbleeding associated with the use of etodolac, ibuprofen, indomethacin, and naproxen in normal males.

Authors:  I L Salom; G Jacob; N Jallad; C A Perdomo; J F Mullane; D Weidler
Journal:  J Clin Pharmacol       Date:  1984 May-Jun       Impact factor: 3.126

6.  S.E.M. study I: Gastric and duodenal lesions induced by non-steroidal anti-inflammatory drugs (aspirin, piroxicam) in man.

Authors:  G Zoli; G Pasquinelli; F Bonvicini; G Gasbarrini; R Laschi
Journal:  Int J Tissue React       Date:  1986

7.  The effects of ibuprofen, indomethacin, aspirin, naproxen, and placebo on the gastric mucosa of normal volunteers: a gastroscopic and photographic study.

Authors:  F L Lanza; G L Royer; R S Nelson; T T Chen; C E Seckman; M F Rack
Journal:  Dig Dis Sci       Date:  1979-11       Impact factor: 3.199

8.  Chlortenoxicam pharmacokinetics in young and elderly human volunteers.

Authors:  S I Ankier; A E Brimelow; P Crome; A Johnston; S J Warrington; P Turner; H P Ferber
Journal:  Postgrad Med J       Date:  1988-10       Impact factor: 2.401

9.  A double-blind randomized placebo controlled gastroscopic study to compare the effects of indomethacin capsules and indomethacin suppositories on the gastric mucosa of human volunteers.

Authors:  F L Lanza; E R Umbenhauer; R S Nelson; M F Rack; C P Daurio; L A White
Journal:  J Rheumatol       Date:  1982 May-Jun       Impact factor: 4.666

10.  Gastrointestinal blood loss in arthritic patients receiving chronic dosing with etodolac and piroxicam.

Authors:  N S Jallad; M Sanda; I L Salom; C S Perdomo; D C Garg; J F Mullane; D J Weidler
Journal:  Am J Med Sci       Date:  1986-11       Impact factor: 2.378

View more
  2 in total

1.  A double blind, multicentre, placebo controlled trial of lornoxicam in patients with osteoarthritis of the hip and knee.

Authors:  H Berry; H A Bird; C Black; D R Blake; A M Freeman; D N Golding; E B Hamilton; M I Jayson; B Kidd; H Kohn
Journal:  Ann Rheum Dis       Date:  1992-02       Impact factor: 19.103

Review 2.  Lornoxicam. A review of its pharmacology and therapeutic potential in the management of painful and inflammatory conditions.

Authors:  J A Balfour; A Fitton; L B Barradell
Journal:  Drugs       Date:  1996-04       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.